In April 2018, the American Academy of Neurology (AAN) issued a new practice guideline on the use of disease-modifying therapies (DMTs) in adults with MS. Included in this document are recommendations concerning when and how to switch DMTs. It is incumbent on MS-treating clinicians to be knowledgeable about these recommendations and be prepared to implement them in clinical practice. This program is designed to address these recent recommendations and to facilitate their timely incorporation into clinical practice.
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category Credits™
.png)
Highly active multiple sclerosis (HAMS) is a chronic, inflammatory and degenerative disorder that results in rapid and profound accrual of neurological disability. The 2018 AAN Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis now suggest that specific agents be offered to individuals with HAMS. Clinicians must have a thorough understanding of the efficacy and safety profiles of these therapies and be able to make recommendations based on a patient’s preferences and risk tolerance. In addition, ongoing surveillance for medication adherence, adverse events, relapses, and disability accumulation is essential.
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category Credits™
|